May 30, 2019 10:25 AM EDT
News Briefing

Novo's in­vest­ment arm in­jects $67.5M in Ox­ford Bio­med­ica; Aba­cus Med­i­cine de­lays IPO plans

Natalie Grover

Reporter

→ The in­vest­ment arm of Dan­ish drug­mak­er No­vo Nordisk $NVO is in­vest­ing £53.5 mil­lion (about $67.5 mil­lion) in UK-based gene and cell ther­a­py group …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Sage sues Bio­gen days af­ter $469M buy­out of­fer

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

What Trump's CMS can and can't change with the sec­ond round of drug price ne­go­ti­a­tions

Up­dat­ed: J&J to buy In­tra-Cel­lu­lar for $14.6B in lat­est neu­ro­science bet

Kathy High leads GV, ARCH-backed eye dis­ease biotech; Arv­inas com­mer­cial ex­ec steps down

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

A service from the Financial Times